Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management
Keywords: type 2 diabetes, GLP-1 receptor agonists
AbstractDespite advances in options for the treatment of type 2 diabetes, optimal glycaemic control is often not achieved. Hypoglycaemia and weight gain that are associated with many antidiabetic medications may interfere with the implementation and long-term application of treatment strategies. Glucose homeostasis is dependent on a complex interplay of multiple hormones and gastrointestinal peptides, including glucagon-like peptide 1 (GLP-1). Abnormal regulation of these substances may contribute to the clinical presentation of diabetes. GLP-1-based therapies affect glucose control without causing hypoglycaemia through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric emptying, regulation of postprandial glucagon and reduction of food intake.
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.